微型RNA市场－2026-2031年预测

预计到 2025 年， 微型RNA市场规模将达到 18.22 亿美元，到 2031 年将达到 37.64 亿美元，复合年增长率为 12.85%。

微型RNA市场正经历强劲成长，预计2024年市场规模将达到18亿至20亿美元，到2034年将达到60亿至100亿美元，复合年增长率（CAGR）为12%至19%。这一增长主要得益于探索微型RNA在诊断和治疗中作用的临床试验数量的增加，尤其是在癌症等复杂疾病领域。癌症发生率的上升正在加速对基于微型RNA的生物标记和个人化疗法的需求。生技公司正在不断创新研究、诊断和治疗的工具，其应用范围也不断扩大，涵盖农业、兽医学和环境监测等领域。

微型RNA （miRNA）是长度21-25个核苷酸的小型非编码RNA分子，可在转录后水平调控基因表现。其异常表达与多种疾病相关，使其成为生物标记、治疗标靶和调控因子。市场涵盖研究工具（谱分析、定序盒）、服务（功能分析、客製化合成）和新兴疗法（模拟物、抑制剂）。成长要素包括miRNA在癌症、心血管疾病、神经系统疾病和感染疾病等领域的广泛应用潜力，以及次世代定序（NGS）、生物资讯学和递送系统等技术的协同效应。

临床试验数量的活性化是关键驱动因素。诸如clinicaltrials.gov之类的平台列出了正在进行的针对固态肿瘤、骨髓恶性肿瘤和慢性疾病中miRNA通路的研究。癌症的高发生率（占发病率的很大一部分）推动了miRNA作为非侵入性生物标记和肿瘤抑制性miRNA（癌基因）的应用。向个人化医疗的转变正在利用miRNA谱进行患者分层和个人化治疗。

机会包括将应用范围拓展到人类健康以外的领域，例如植物和农业性状改良、兽医诊断以及利用miRNA特征进行生态系统监测。资金流入正在支持研发管线的推进，候选药物正处于临床前和早期临床阶段。

阻碍因素包括对 miRNA 网路的了解有限、特异性递送方面的挑战（稳定性、脱靶效应）、临床效用的严格检验以及治疗核准的监管障碍。

按地区划分，北美占40-48%的市场份额，这主要得益于其先进的研究基础设施、充足的研发资金、较高的慢性病负担以及众多主要企业的集中。美国凭藉美国主导卫生研究院（NIH）主导的各项计画和生物技术中心，在该领域主导地位。亚太地区将呈现最高的复合年增长率（高达21%），这主要得益于其庞大的人口基数、不断增长的医疗保健投资，以及中国、日本和印度对基因组学研究的重视。

主要企业包括 Thermo Fisher Scientific（分析/定序工具）、QIAGEN（样本到洞察工作流程）、Illumina（次世代定序平台）、Horizo​​​​n Discovery（编辑/调节试剂）、Biogenex（ISH 检测），以及 Regulus 和 Miragen 等新兴治疗公司，这些公司正在推动灵敏度、生物检测水平和临床资讯整合的临床研究和临床学抑制剂/临床研究因子。

总体而言，市场正在动态发展， 微型RNA的多方面作用促进了在慢性病日益增多和技术融合的背景下的精准诊断和治疗。

本报告的主要优势：

• 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用这些见解，在快速变化的环境中做出策略决策，并发现新的商机和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业如何使用我们的报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

研究范围：

• 2021年至2025年的历史数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章微型RNA市场类型

• 介绍
• 产品
• 服务

第六章 依应用分類的微型RNA市场

• 介绍
• 癌症
• 感染疾病
• 免疫疾病
• 心血管疾病
• 神经系统疾病
• 其他的

第七章 依最终用户分類的微型RNA市场

• 介绍
• 生物技术和製药公司
• 学术和政府研究机构
• 其他最终用户

第八章 各地区的微型RNA市场

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• QIAGEN
• BioGenex
• GeneCopoeia, Inc.
• NanoString
• Quantabio
• SeqMatic LLC
• OriGene Technologies, Inc.
• Illumina, Inc.

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

MicroRNA Market, at a 12.85% CAGR, is anticipated to reach USD 3.764 billion in 2031 from USD 1.822 billion in 2025.

The microRNA market is experiencing robust growth, with estimates placing its value between USD 1.8-2.0 billion in 2024 and projections reaching USD 6-10 billion by 2034, reflecting CAGRs of 12-19%. This expansion is fueled by escalating clinical trials exploring microRNA's diagnostic and therapeutic roles in complex diseases, particularly cancer. Rising cancer prevalence is accelerating demand for microRNA-based biomarkers and personalized therapies. Biotech firms are innovating tools for research, diagnostics, and treatments, while applications extend into agriculture, veterinary medicine, and environmental monitoring.

MicroRNAs (miRNAs) are small, non-coding RNA molecules (21-25 nucleotides) that regulate gene expression post-transcriptionally. Their dysregulation links to numerous pathologies, positioning them as biomarkers, therapeutic targets, and modulators. The market encompasses research tools (profiling assays, sequencing kits), services (functional analysis, custom synthesis), and emerging therapeutics (mimics, inhibitors). Growth stems from miRNA's broad-spectrum potential in oncology, cardiovascular, neurological, and infectious diseases, alongside technological synergies in NGS, bioinformatics, and delivery systems.

Primary drivers include intensifying clinical trials, with platforms like clinicaltrials.gov listing ongoing studies targeting miRNA pathways in solid tumors, hematological malignancies, and chronic conditions. Cancer's dominance-accounting for significant morbidity-propels miRNA as non-invasive biomarkers and oncomiR suppressors. The shift toward personalized medicine leverages miRNA profiles for patient stratification and tailored interventions.

Opportunities lie in diversifying applications beyond human health, including plant/agricultural trait enhancement, veterinary diagnostics, and ecological monitoring via miRNA signatures. Funding influxes support pipeline advancement, with candidates progressing through preclinical and early clinical phases.

Restraints encompass incomplete understanding of miRNA networks, challenges in specific delivery (stability, off-target effects), stringent validation for clinical utility, and regulatory hurdles for therapeutic approval.

Geographically, North America commands 40-48% share, driven by advanced research infrastructure, substantial R&D funding, high chronic disease burden, and key players' concentration. The U.S. leads through NIH-backed initiatives and biotech hubs. Asia-Pacific exhibits the fastest CAGR (up to 21%), fueled by population scale, rising healthcare investments, and genomic focus in China, Japan, and India.

Leading companies include Thermo Fisher Scientific (profiling/sequencing tools), QIAGEN (sample-to-insight workflows), Illumina (NGS platforms), Horizon Discovery (editing/modulation reagents), BioGenex (ISH detection), and emerging therapeutics firms like Regulus and MiRagen. These entities advance assay sensitivity, bioinformatics integration, and clinical-grade mimics/inhibitors.

Overall, the market is advancing dynamically, with miRNA's multifaceted roles catalyzing precision diagnostics and therapeutics amid chronic disease escalation and technological convergence.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

MicroRNA Market Segmentation

• By Type
• Products
• Services
• By Application
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others
• By End-User
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other End-users
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MICRORNA MARKET BY TYPE

• 5.1. Introduction
• 5.2. Products
• 5.3. Services

6. MICRORNA MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Infectious Diseases
• 6.4. Immunological Disorder
• 6.5. Cardiovascular Disease
• 6.6. Neurological Disease
• 6.7. Others

7. MICRORNA MARKET BY END-USER

• 7.1. Introduction
• 7.2. Biotechnology & Pharmaceutical Companies
• 7.3. Academic & Government Research Institutes
• 7.4. Other end-users

8. MICRORNA MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific, Inc.
• 10.2. Horizon Discovery Ltd.
• 10.3. QIAGEN
• 10.4. BioGenex
• 10.5. GeneCopoeia, Inc.
• 10.6. NanoString
• 10.7. Quantabio
• 10.8. SeqMatic LLC
• 10.9. OriGene Technologies, Inc.
• 10.10. Illumina, Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations